Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
1.055
+0.005 (0.48%)
At close: Apr 1, 2025, 4:00 PM
1.020
-0.035 (-3.32%)
After-hours: Apr 1, 2025, 4:43 PM EDT
Imunon Employees
Imunon had 25 employees as of December 31, 2024. The number of employees decreased by 8 or -24.24% compared to the previous year.
Employees
25
Change (1Y)
-8
Growth (1Y)
-24.24%
Revenue / Employee
n/a
Profits / Employee
-$744,810
Market Cap
15.30M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMNN News
- 8 days ago - IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - GlobeNewsWire
- 4 weeks ago - Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study - GlobeNewsWire
- 4 weeks ago - IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19 - GlobeNewsWire
- 5 weeks ago - IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 - GlobeNewsWire
- 5 weeks ago - IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer - GlobeNewsWire
- 7 weeks ago - IMUNON Appoints Douglas V. Faller, M.D. - GlobeNewsWire
- 3 months ago - IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer - GlobeNewsWire